Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection

Ophthalmology

Volumn 110, Issue 4, 2003, Pages 681-686

  Beer, Paul M ^a   Bakri, Sophie J ^a   Singh, Ravinder J ^b   Liu, Weiguo ^a   Peters III, George B ^c   Miller, Michael ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TRIAMCINOLONE ACETONIDE;

AGED; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; COMPARTMENT MODEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARACENTESIS; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA EDEMA; SOLUBILITY; UVEITIS; VITRECTOMY; VITREOUS BODY;

EID: 0037398304     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01969-3     Document Type: Article

References (20)

1. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-72.
2. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
3. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7.
4. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-7.
5. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
6. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
7. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994;8:66-9.
8. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-7.
9. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-9.
10. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1973;19:716-23.
11. Grasela TH Jr. Population pharmacokinetics: application to clinical trials. In: Smith RB, Kroboth PD, Juhl RP, eds. Pharmacokinetics and Pharmacodynamics: Research Design and Analysis. Cincinnati, OH: Harvey Whitney Books, 1986:85-103.
12. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol 1995;113:867-9.
13. Madu AA, Mayers M, Perkins R, et al. Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 1996;63:129-36.
14. Drusano GL, Liu W, Perkins R, et al. Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program. Antimicrob Agents Chemother 1995;39:1683-7.
15. Perkins RJ, Liu W, Drusano G, et al. Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits. Antimicrob Agents Chemother 1995;39:1493-8.
16. Miller MH, Madu A, Samathanam G, et al. Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. Antimicrob Agents Chemother 1992;36:32-8.
17. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998;42:1417-23.
18. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-6.
19. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
20. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75.